Agree
. Update is due. Plenty of cash.
NSB is working with a highly experienced and qualified regulatory consultancy that holdsoffices in UK, EU, US and Australia, to ensure that NSB can gain as much insight from the FDAand confirm that the development plan in place for EmtinB within Ophthalmology is withinthe regulator's expectations to allow the initiation of a clinical trial.It is expected that this submission will occur in Q1 2024.
EmtinB™ Early Phase Clinical StudyThe Company’s Early Phase Clinical Study data is locked and is awaiting a finalised statisticalreport from its collaborator to allow for a thorough process of interpretation and reporting.The interpretation of this data is expected in Q1 2024.
IMO
- Forums
- ASX - By Stock
- Ann: NSB Receives A$2.2M Research & Development Tax Refund
Agree. Update is due. Plenty of cash. NSB is working with a...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NSB (ASX) to my watchlist
|
|||||
Last
3.9¢ |
Change
-0.001(2.50%) |
Mkt cap ! $5.639M |
Open | High | Low | Value | Volume |
3.7¢ | 3.9¢ | 3.7¢ | $5.263K | 139.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.9¢ | 27000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 100000 | 0.038 |
3 | 54382 | 0.037 |
1 | 300000 | 0.036 |
3 | 292350 | 0.035 |
1 | 600000 | 0.033 |
Price($) | Vol. | No. |
---|---|---|
0.039 | 27000 | 1 |
0.040 | 199999 | 1 |
0.046 | 279261 | 1 |
0.048 | 344382 | 1 |
0.050 | 1086 | 1 |
Last trade - 15.44pm 31/07/2024 (20 minute delay) ? |
Featured News
NSB (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, CEO
Anthony Noble
CEO
SPONSORED BY The Market Online